Skip to content

Resilience and Equity in Aging, Cancer, and Health (REACH)

Resilience and Equity in Aging, Cancer, and Health (REACH): Promoting Physical Resilience and Cancer Care Equity for Adults Age 65 and Older Diagnosed With Gastrointestinal Malignancy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04674267
Acronym
REACH
Enrollment
147
Registered
2020-12-19
Start date
2022-01-18
Completion date
2026-12-31
Last updated
2026-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer, Esophageal Cancer, Gastric Cancer, Gastrointestinal Cancer, Pancreatic Cancer, Rectal Cancer

Keywords

Gastrointestinal cancer

Brief summary

The purpose of this multi-phase research study is to understand how consultation of cancer care with a geriatrician can best improve outcomes for older adults with gastrointestinal malignancies.

Detailed description

This research study will be conducted in three phases: * Phase 1 - Needs assessment and implementation plan * Phase 2 - Pilot Intervention * Phase 3 - Expanded Clinical Trial * Please note Phase 2 - Pilot Intervention and Phase 3 - Expanded Clinical Trial will be added to the clinicaltrials.gov record once Institutional Review Board (IRB) approved. Phase 1 is composed of three aims and will inform the subsequent two phases:. * Aim 1: To evaluate the perceived needs of Older Adults diagnosed with gastrointestinal malignancies, caregivers, staff, and faculty to characterize the implementation setting for a geriatric consultation. * Aim 2: To refine the proposed REACH program implementation plan based on qualitative feedback provided by Older Adult (OA) patients, their identified caregivers, staff, and faculty. * Aim 3: Determine the patient, demographic, social determinants, clinical and disease characteristics of Older Adults (OA) associated with ED visits/hospitalization following initial oncology consultation at DF/BWCC in year 2019. * Phase 2 intervention has started as of January 2022 following IRB approval. Study team has begun recruiting participants into Phase 2 intervention of REACH study starting in January 2022. Participants approached by REACH coordinator for consenting and enrollment after their initial consult visit at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC). Participants are then asked to complete an electronic fitness assessment (EFA) that is sent to them via Patient Gateway. Participants complete this questionnaire and receive a score of "Robust", "Pre-frail", or "Frail" - those who score "Pre-frail" or "Frail" will be randomized to meet with a study geriatrician for geriatric co-management intervention alongside their standard oncology care. All enrolled participants will be followed for a duration of 1 year as they are continuing care at DF/BWCC.

Interventions

OTHERPhase 2 Intervention - Geriatric Co-Management

Participants will complete an electronic fitness assessment questionnaire - once completed, they will receive a score of "Robust", "Pre-Frail" or "Frail". Those who are "Pre-frail" or "Frail" will be randomized to meet with a study geriatrician for geriatric co-management in addition to usual oncology care. All participants will be followed for a duration of 1 year.

Sponsors

Dana-Farber Cancer Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who are age 65+ at time of initial consult at DF/BWCC * Diagnosed with a gastrointestinal cancer, including: cancers of the esophagus, stomach, pancreas, liver, bile duct, ampulla, colon, rectum, or anus, as well as neuroendocrine tumors. * Continuing care at DF/BWCC beyond initial consult visit

Exclusion criteria

* Patients less than age 65 at time of initial consultation appointment with DF/BWCC. * Patients who are not continuing care at DF/BWCC beyond first consult visit. * Not proficient in English, Spanish, Haitian Creole, Portuguese, Traditional Chinese, Arabic, or Russian * Patient who are not considered appropriate for enrollment due to complex medical, social, or other situation as determined by their primary oncology team. * Participants with psychiatric illness/social situations that would limit compliance with study requirements.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of electronic fitness assessment questionnaire (developed from Comprehensive Geriatric Assessment tool)1 yearEFA questionnaire deployed to older adult patients age 70+ in the REACH study. Feasibility will be determined by the proportion of participants who consent to complete the electronic fitness assessment. The intervention will be considered feasible if 70% of participants consent to complete the fitness assessment.
Acceptability of electronic fitness assessment questionnaire1 yearAcceptability of electronic fitness assessment questionnaire via the Patient Portal or internet-enabled device following second clinic visit among older adults diagnosed with gastrointestinal cancer seeking consultation at DF/BWCC for medical, radiation, or surgical oncology. Acceptability will be determined by the proportion of participants who fully complete the EFA. The intervention will be considered acceptable if 60% of enrolled participants fully complete the EFA within 14 days of enrollment.
Association of geriatric consultation with number of unplanned ED visits/hospitalizations among older adult participants1 yearAssociation of geriatrician consult with number of ED visits/hospitalizations among older adults diagnosed with gastrointestinal cancer randomized to the geriatric consultation intervention. Randomization will be essential to evaluate the efficacy of geriatric consultation intervention in impacting unplanned ED visits and hospitalizations.

Countries

United States

Contacts

CONTACTNadine A Jackson, MD, MPH
NA_Jackson@dfci.harvard.edu877-442-3324
CONTACTNadine J McCleary, MD, MPH
NJ_McCleary@dfci.harvard.edu877-442-3324
PRINCIPAL_INVESTIGATORNadine A Jackson, MD, MPH

Dana-Farber Cancer Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 11, 2026